AC Immune (NASDAQ:ACIU) Issues Earnings Results

AC Immune (NASDAQ:ACIU) issued its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06, FiscalAI reports. The firm had revenue of $3.88 million for the quarter, compared to analyst estimates of $0.33 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%.

AC Immune Trading Up 7.9%

Shares of ACIU traded up $0.17 on Wednesday, reaching $2.25. The company’s stock had a trading volume of 155,504 shares, compared to its average volume of 265,633. AC Immune has a twelve month low of $2.02 and a twelve month high of $3.90. The stock has a market capitalization of $229.49 million, a PE ratio of -4.18 and a beta of 1.64. The firm has a fifty day moving average of $2.58 and a 200-day moving average of $2.72.

Wall Street Analysts Forecast Growth

ACIU has been the topic of a number of research reports. Zacks Research downgraded shares of AC Immune from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 28th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research note on Wednesday, September 23rd. HC Wainwright reiterated a “buy” rating on shares of AC Immune in a report on Thursday, September 24th. Finally, Weiss Ratings cut shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 20th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, AC Immune currently has a consensus rating of “Hold” and a consensus price target of $7.50.

AC Immune Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.